CADILAHC.NS : Summary for CADILA HEALTHCARE INR1 - Yahoo Finance

U.S. Markets closed

Cadila Healthcare Limited (CADILAHC.NS)

NSE - NSE Delayed Price. Currency in INR
Add to watchlist
395.80-4.15 (-1.04%)
At close: 4:59 AM EST
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close399.95
Bid0.00 x
Ask395.80 x
Day's Range390.95 - 401.25
52 Week Range295.00 - 429.80
Avg. Volume670,695
Market Cap405.35B
PE Ratio (TTM)31.63
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Reuters3 months ago

    Serbian state pharma tender attracts only one valid bid

    A tender for a 25 percent stake in Serbia's loss-making, state-owned pharmaceutical company Galenika has attracted only one valid bid, the Economy Ministry said on Thursday. Serbia has promised to sell, shut or slim down unprofitable state firms to fulfil the conditions of a 1.2 billion euro ($1.4 billion) loan deal with the International Monetary Fund, but bidders for generously-staffed, indebted companies have been hard to find. Other state companies for which Serbia is seeking buyers include the RTB Bor copper mine and the Resavica coal mine.

  • Reuters4 months ago

    Three companies submit offers for Serbia's Galenika drug maker

    An Indian company, a Brazilian company and a British-Russian consortium have bid for a 25 percent stake in Serbia's Galenika pharmaceutical maker which has debts of $220 million, the Economy Ministry said on Wednesday. In April the ministry invited strategic partners to invest at least 7 million euros ($7.7 million) in Galenika, which operates drug manufacturing plants, for at least five years. In a statement the ministry said Cadila Pharmaceuticals Limited from India, Brazil's EMS S.A. and the consortium of Britain's Frontier Pharma Limited and Russian LLC NPA Petrovax Pharm submitted valid offers.

  • Reuters5 months ago

    Mayne Pharma nears deal for Teva assets -source

    Australia's Mayne Pharma Group Ltd on Tuesday said it will acquire U.S. generic products from Teva Pharmaceuticals for $652 million, helping it propel into the top 2 in the general oral contraceptives market in the United States. Mayne will raise A$601 million ($440.89 million) for a 1-for-1.725 rights issue and a share placement offer of A$287 million to fund the acquisition, it said in a statement on Tuesday. "The acquisition substantially increases and diversifies Mayne Pharma's earnings across more products, therapeutic areas, dosage forms and complex technologies," it added.